Channel Partner Agreement Signed
Building a Business Model Integrating Equipment, Diagnostic Panels, and AI Analysis Software
Pursuing ODM and OEM Collaboration in Southeast Asia and Africa

NGEN Bio announced on July 16 that it has signed a channel partner agreement with global genomics company Illumina for the distribution of next-generation sequencing (NGS) equipment and array technology.


From the left, company logo images of Ngenbio and Illumina. Ngenbio

From the left, company logo images of Ngenbio and Illumina. Ngenbio

View original image

With this agreement, NGEN Bio will now be able to supply Illumina's NGS equipment in Korea in addition to its existing diagnostic panels and AI-based analysis software businesses. The company plans to establish an integrated NGS business model connecting equipment, diagnostic panels, and analysis software.


Until now, NGEN Bio has developed and supplied diagnostic panels and analysis software based on the Illumina platform, focusing on precision diagnostics for major general hospitals in Korea. Recently, the company has been expanding the supply of its diagnostic panels to Southeast Asian markets, including Vietnam.


Based on its existing medical institution network, the company will begin supplying Illumina NGS equipment and plans to strengthen its integrated solutions business by combining its proprietary diagnostic panels with analysis software.


The two companies also intend to review the possibility of collaborating on ODM and OEM business targeting Southeast Asian and African markets by utilizing NGEN Bio's diagnostic panels and analysis software.



Minshik Kim, CEO of NGEN Bio, said, "Through this partnership, we will expand our NGS business sector and enhance our competitiveness in precision medicine, leveraging domestic and international partnerships."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing